Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologyDiseaseAdenoid Cystic CarcinomaSubgroupICD10C44.-MeSHCarcinoma, Adenoid CysticSequenceChemotherapyChemo-substanceLenvatinibChemo-substanceLenvatinibChemo-substanceLenvatinibChemo-substanceLenvatinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksCardiotoxicityEmetogenicityHemorrhageHypertensionPainProteinuria only studiesPublicationAuthorTchekmedyian, VDiseasefortschreitendes, nicht heilbares adenoid-zystisches Karzinom, Erst (nach Bestrahlung)- und Zweitlinie, ECOG 0-1OriginMemorial Sloan Kettering Cancer Center, New York, NYProtocols in Revision 1 protocol foundProtocols under revision.Lenvatinib 24, Adenoid Cystic Carcinoma (PID670 V1.1)
